Changes

Jump to: navigation, search

Avatrombopag (Doptelet)

293 bytes added, 14:37, 21 May 2018
m
no edit summary
Thrombopoietin receptor agonist
==Preliminary dataDiseases for which it is used=====*[[Autoimmune thrombocytopenic purpura (ITP)]]===
# Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. [http://bloodjournal.hematologylibrary.org/content/123/25/3887.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24802775 PubMed]
*[[Thrombocytopenia in liver disease]]
 
==History of changes in FDA indication==
* 5/21/2018: FDA approved "for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] scheduled to undergo a procedure."
==Also known as==
*'''Code names:''' E5501, YM477, AKR 501*'''Brand name:''' Doptelet
[[Category:Drug index]]
[[Category:Immune thrombocytopenic purpura (ITP) medications]]
[[Category:InvestigationalDrugs FDA approved in 2018]]
LookupUsers, editors, emailconfirmed
23,523
edits

Navigation menu